NCT03335839

Adjunctive, Low-dose tPA in Primary PCI for STEMI

Adjunctive, Low-dose Intracoronary Recombinant Tissue Plasminogen Activator (tPA) Versus Placebo for Primary PCI in Patients With ST-segment Elevation Myocardial Infarction

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 210 (actual)
• Sponsor: Population Health Research Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

STRIVE will evaluate the use of adjunctive, low-dose intracoronary tissue plasminogen activator during primary percutaneous coronary intervention (PCI) for patients with ST elevation myocardial infarction (STEMI) in reducing the incidence of post-procedural myocardial blush (MBG) grade 0/1 or distal embolization.

Detailed description

STRIVE is a prospective, 3-arm, parallel group, blinded, randomized controlled trial evaluating the efficacy of a novel approach to prevent and treat microvascular obstruction thereby reducing major cardiovascular events using intracoronary administration of very low-dose fibrinolytic (tissue plasminogen activator, tPA) directly into the culprit coronary artery during primary PCI.

Conditions

• Myocardial Infarction
• Percutaneous Coronary Intervention

Interventions

Type	Name	Description
DRUG	tissue plasminogen activator	Recombinant tPA is a fibrin-specific 2nd generation plasminogen activator and thrombolytic drug.
OTHER	Saline	Placebo

Timeline

• Start date: 2018-04-01
• Primary completion: 2024-09-17
• Completion: 2025-02-12
• First posted: 2017-11-08
• Last updated: 2025-09-26

Locations

3 sites across 1 country: Canada